Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: 3QFY02 net up 36% - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jan 22, 2002

    Sun Pharma: 3QFY02 net up 36%

    Sun Pharmaceuticals has posted a growth of 36% in net profit for 3QFY02, compared to the corresponding period last fiscal. Sales has jumped by more than 25% to touch Rs 1,968 m. On a sequential basis however, revenues have remained flat. Operating margins increased by 160 basis points to 26.5%, which is amongst the best in the industry.

    (Rs m) 3QFY01 3QFY02 Change
    Sales 1,578 1,968 24.7%
    Other Income 10 12 18.8%
    Expenditure 1,185 1,446 22.1%
    Operating Profit (EBDIT) 394 522 32.5%
    Operating Profit Margin (%) 24.9% 26.5%  
    Interest (4) (12.7) 217.5%
    Depreciation 40 44 9.5%
    Profit before Tax 368 502.8 36.6%
    Other Adjustments   -  
    Tax 27 39 41.2%
    Profit after Tax/(Loss) 341 464 36.3%
    Net profit margin (%) 21.6% 23.6%  
    No. of Shares (eoy) (m) 46.8 46.8  
    Diluted Earnings per share* 29.1 39.7  
    P/E (at current price)   16.2  

    The sales performance was fuelled by 33% growth in exports, particularly bulk exports. On the other hand, domestic sales also grew at a healthy rate of 23%, far outperforming industry growth rates. The growth in domestic market was on the back of aggressive launch of new products. Sun Pharma has launched 10 new products in last six months.

    Sun Pharma recently informed that Caraco Pharma, its US subsidiary, has received a approval for manufacturing and marketing metformin in the US markets, which is a generic name for US$ 1.8 bn drug Glucophage. Over the last six months, Caraco has received 4 drug approvals and is targeting 5 more approvals by the end of the year.

    The stock price of the company has moved up sharply after the company announced drug approvals for Caraco Pharma. Markets are expecting that the company would stick to its target of achieving breakeven in Caraco Pharma by the end of the current year. At Rs 642, the company trades at a P/E multiple of 16x annualised earnings for 3QFY02. The performance of Caraco and time taken for its turnaround would be the key valuation driver going forward.



    Equitymaster requests your view! Post a comment on "Sun Pharma: 3QFY02 net up 36%". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 (Close)


    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts